In cell and animal models, telomere erosion promotes chromosomal instability via breakage-fusion-bridge cycles, contributing to the early stages of tumorigenesis. However, evidence involving short telomeres in cancer development in humans is scarce, epidemiological and indirect. Here we directly implicate telomere shortening as a critical molecular event for malignant evolution in aplastic anemia (AA). Patients' telomere lengths at diagnosis of AA, while comparable to age-matched controls, inversely correlated with the probability of developing a cytogenetically abnormal clone. A significantly increased number of telomere signal-free chromosomal ends and chromosomal numerical and structural abnormalities were observed in bone marrow cells of patients with shorter telomeres in comparison with patients with longer telomeres and healthy subjects. The proportion of monosomy-7 cells in the bone marrow at diagnosis of AA inversely correlated with telomere length, years before the emergence of an autonomous and clinically detectable abnormal clone. Marrow cells of clinically healthy individuals carrying loss-of-function telomerase mutations and with extremely short telomeres also showed chromosomal instability in vitro. These results provide the first clinical direct evidence in humans that short telomeres in hematopoietic cells are dysfunctional, mediate chromosomal instability and predispose to malignant transformation in a human disease.
Introduction
Aplastic anemia (AA) is a human disease characterized by marked reduction in the quantity and quality of hematopoietic progenitor and stem cells. 1 The bone marrow, normally cellular with precursors of granulocytes, erythrocytes and platelets, is replaced by fat, resulting in low peripheral blood cell counts. Untreated, patients with AA die from the consequences of anemia (congestive heart failure), severe bacterial or fungal infections that develop in the absence of neutrophils, or from bleeding due to low platelet counts. In most patients with acquired AA, hematopoietic progenitors are targeted by cytotoxic T-cells, leading to immune-mediated destruction of hematopoiesis. 1 Patients can be effectively treated with replacement of the hematopoietic and immune systems by stem cell transplantation or by immunosuppressive therapies, mainly antithymocyte globulin and cyclosporine. 1 In a minority of patients, loss-of-function mutations in telomerase complex genes predispose to marrow failure through accelerated telomere erosion that limits the proliferative capacity of hematopoietic cells. 2, 3 The classical human disease caused by telomere erosion is dyskeratosis congenita, an inherited type of AA of childhood associated with mucocutaneous anomalies, in which mutations in telomerase are etiologic. [3] [4] [5] [6] [7] About 15% of patients with acquired AA undergo evolution of their disease to a bone marrow malignancy, typically myelodysplasia or acute myeloid leukemia, sometimes years after good hematologic recovery with immunosuppressive therapies. 8, 9 AA is thus, a model of an inflammatory disease with malignant potential.
Indirect clinical and epidemiological evidence as well as murine models suggest that telomere shortening promotes chromosomal instability and predisposes to cancer. In dyskeratosis congenita, patients have an almost 200-fold higher probability of developing acute myeloid leukemia and more than 1000-fold greater risk of squamous cell carcinoma. 10 Telomerase mutations also occur in patients with sporadic de novo 11 or familial 12 acute myeloid leukemia. In addition, sequence variants in the TERT-CLPTM1L locus (5p15.33) have been implicated as a major susceptibility region for a variety of human cancers, 13, 14 and in a recent population-based study, telomere length inversely correlated with the risk of developing many cancers. 15 However, direct evidence establishing how telomeres are dysfunctional and how they promote cancer susceptibility has yet to be demonstrated in human cells.
Mice lacking the RNA component of telomerase and deficient in p53 expression show chromosomal instability, non-reciprocal translocation of chromosomes and an increased rate of epithelial cancers. 16 Also in Terc 'knockout' murine models, telomere dysfunction causing chromosomal changes preferentially occur in chromosomes with critically short telomeres. 17 In addition, conditional Trp53 'knock-out' in the intestinal epithelium of Terc À/À mice promotes an accumulation of chromosomal unstable intestinal stem cells and abnormal epithelial cell differentiation. 18 These observations in murine models suggest that telomere erosion causes telomere dysfunction and mediates chromosomal instability; if telomere dysfunction behaves similarly in human cells, this could explain the clinical association of short telomeres and cancer development.
Here we investigated whether short telomeres independent of telomerase mutations mediated chromosomal instability in human AA, a 'benign' hematopoietic disease with proclivity to hematologic cancers, and consequently predisposed to malignant transformation.
Patients and methods

Patients and controls
Peripheral blood samples were obtained at diagnosis from 183 unrelated consecutive patients who fulfilled entry criteria for acquired AA and enrolled in three sequential protocols at the National Institutes of Health Clinical Center from 2003 to 2008 (ClinicalTrials. gov numbers, NCT00001964, NCT00260689 and NCT00061360). None of the patients had received previous immunosuppressive therapy. In all, 153 patients received horseanti-thymocyte globulin (ATGAM, Pfizer, Kalamazoo, MI, USA) and cyclosporine A, and 30 received rabbit-anti-thymocyte globulin (Thymoglobulin, Genzyme, Cambridge, MA, USA) and cyclosporine A. 19 Of the 183 patients, 105 were male (57%) and 78 were female (43%); median age was 35 years (range, 2-83 years). DNA from peripheral blood leukocytes also was obtained from 175 healthy volunteers ranging in age from 0 to 99 years (median age was 36 years), as previously described. 20 All samples were collected after informed consent was obtained according to protocols approved by NHLBI Institutional Review Board and University of Sao Paulo local ethics committee (healthy subjects); for umbilical cord blood samples, informed consent was waived by our Institutional Review Board.
Telomere length by quantitative PCR assay
Telomere length of peripheral blood leukocytes was assessed by quantitative PCR as previously described. 21 
Fluorescence in situ hybridization (FISH)
Frozen bone marrow samples of 39 AA patients collected at first diagnosis were assayed for monosomy 7 by interphase FISH. After thawing, cells were re-suspended in Carnoy's fixative three times, dropped on slides in a humidifier chamber and probed for chromosome 7 (Abbott Molecular, Des Plaines, IL, USA). The percentage of monosomy-7 cells was enumerated by two independent observers, who were blinded to telomere length results.
Frozen bone marrow cells from 5 healthy volunteers, 12 patients with AA with shorter telomeres (in the lower quartile) and 7 patients with longer telomeres (in the upper quartile) collected 6 months after initial therapy were examined for telomere signal-free ends. Patients were selected based on telomere length and sample availability. Samples were thawed and cultured in semi-solid media (methylcellulose) containing cytokines (stem cell factor, granulocyte-macrophage-colony stimulating factor, erythropoietin and interleukin 3, Stem Cell Technologies, Vancouver, BC, Canada) supplemented with granulocyte-colony stimulating factor at 400 ng/ml for 7 days. Colcemid at 10 ng/ml was added to culture for 2 hours, cells were harvested and resuspended in hypotonic solution (75 mM KCl) for 20min at 371C. Cells were resuspended in Carnoy's fixative three times, and dropped on slides in a humidifier chamber. Telomere-free ends were detected by FISH with an Alexa-488-labeled PNA probe (Panangene, Daejeon, South Korea). Telomere-free ends were determined as an absence of detectable fluorescence signal at telomeres after background subtraction.
We obtained bone marrow samples from three clinically healthy subjects who carried a telomerase mutation and in whom leukocytes had very short telomeres. These individuals' marrow cells were assessed by FISH for monosomy 7 and trisomy 8 before and after a 3-day period of cell culture. For each subject, experiments were performed in duplicate and aneuploid cells were enumerated by two independent observers.
Spectral karyotyping (SKY)
Bone marrow samples from four healthy controls, nine patients with shorter telomeres (in the lower quartile) and six patients with longer telomeres (in the upper quartile) were used for detection of telomere-free ends were analyzed by SKY, as previously described. 22 Patients' samples were selected based on the availability of frozen bone marrow cells. Quantitation followed the ISCN (International System for Human Cytogenetic Nomenclature) 2009 definitions and recommendations, in which a clone is defined if at least two cells have the same chromosome gain or structural alteration and at least in three cells if the aberration is a loss of chromosome.
Statistical methods
A patient's 'predicted telomere length' was computed from the predicted value (a þ b Â age) by fitting the linear regression model Y ¼ a þ b Â age þ e to the sample of 183 AA patients, where a and b were the least-squares estimates of a and b, respectively. P-values based on the w 2 tests and the subjects in the SKY samples were used to evaluate the differences in the frequency of karyotypic abnormalities. Numerical results were computed using the S-PLUS statistical package (TIBCO Inc., Palo Alto, CA, USA) and Prism (Prism Software Corporation, Orange County, CA, USA).
Results
Telomere length and the risk of malignant transformation
Using quantitative PCR, we measured the mean telomere length of peripheral blood leukocytes of 183 consecutive treatmentnaive patients with acquired AA from blood samples collected early in their course. These patients subsequently received immunosuppressive treatment at the NIH Clinical Center. Telomeres of 175 age-matched healthy volunteers also were measured.
We found that the telomere lengths of acquired AA patients shortened with aging and superimposed on those of healthy subjects (Figure 1a ), indicating that the telomere lengths of aplastic patients were not shorter but comparable to those of age-matched healthy individuals. All patients were tested for mutations in genes of the telomerase complex and only one was positive: heterozygous for a TERT A202T mutation with telomere length below the 10th percentile of age-matched healthy controls. 2 We have recently reported in the same cohort of patients with severe acquired AA that those who have shorter telomeres (in the lower quartile for age-adjusted telomere length) have a three-fold higher probability of progression to myelodysplasia and/or leukemia than do aplastic patients with telomere lengths in the upper three quartiles. 21 Here, we updated, expanded and detailed this clinical observation. First, we identified all patients who have evolved to date, classified based on karyotypic change, and analyzed their telomere lengths according to age. We observed that most patients who eventually developed an abnormal karyotype had their telomere length below the agematched average (Figure 1b) . This difference was even more evident for patients who developed clinically significant abnormal karyotypes, namely monosomy 7 or complex karyotype ( Figure 1b ). As patients did not have shorter telomeres in comparison with age-matched healthy individuals (Figure 1a ), they were then divided into the four quartiles according to the age-adjusted telomere length and each quartile was analyzed separately; we confirmed that telomere length inversely correlated with the hazard of an abnormal karyotype after immunosuppressive therapy (log-rank P ¼ 0.06). However, this inverse correlation was restricted only to patients in the first (lower) quartile, which had a significant increase in the risk of clonal evolution (24.5%); patients in the other three quartiles had similar risk of clonal progression (4.8-10.7%; Figure 1c ).
In the clinical setting, not all karyotypic abnormalities are linked to a poor outcome; so we focused our analysis on malignant evolution events known to be associated with a high likelihood of leukemic transformation and poor survival (monosomy 7 and complex karyotypes). 23 The risk of developing a malignant clone increased as the age-adjusted telomere length shortened: patients in the upper two quartiles (longer telomeres) had a very low risk of malignant transformation (2.5%) in comparison with those in the second quartile (8.3%) and in the first (lowest) quartile (18.8%; log-rank P ¼ 0.018; Figure 1d ). Together, these results indicate that telomere length of hematopoietic cells antedated and inversely correlated with progression to clonal hematopoietic malignancy with abnormal karyotypes.
Telomere length inversely correlates with aneuploid cells
All patients in our cohort had normal karyotypes by conventional cytogenetics at diagnosis. We then employed a more sensitive method, FISH, in order to detect chromosomal aneuploidy in bone marrow cells of samples collected at diagnosis. FISH was applied to samples of 39 unselected patients from the cohort, in whom conventional cytogenetics were normal, to determine the number of chromosome 7 per cell; FISH evaluates both dividing (metaphase) and non-dividing (interphase) cells. We found a strong inverse correlation between average leukocyte telomere length and the percentage of monosomy-7 cells by FISH in the marrow (Spearman r ¼ À0.503; P ¼ 0.001; Figure 2a ). Chromosomally abnormal cells in AA patients with initial normal karyotype have been previously reported, but their significance remained unclear. 24, 25 Some of these clonal cells are not autonomous and eventually disappear in the long term.
Short average telomere length correlates with the shortest telomeres
Although the average leukocyte telomere length inversely correlated with malignant clonal evolution, it has been demonstrated that its not the average telomere length but rather the shortest telomeres that cause telomere dysfunction and chromosomal instability in mouse models. 17 We sought to identify the shortest (and dysfunctional) telomeres by measuring the proportion of telomere signal-free ends. Signal-free ends Figure 1 Short average leukocyte telomere length associates with dysfunctional telomeres and chromosomal instability. (a) Telomere length was measured pre-treatment using qPCR in 183 consecutive patients with acquired aplastic anemia (blue circles) and 175 healthy volunteers (yellow circles) and represents the y axis, measured in T/S ratio (x axis represent the age in years). Telomere length distribution with age was not different between patients and controls (analysis of variance-F test). Solid line corresponds to the regression line for aplastic anemia patients, whereas the dashed line represents the regression line for healthy subjects. (b) Most patients with acquired aplastic anemia who eventually developed a cytogenetic abnormality had pre-treatment telomere lengths below the mean for age-matched controls. Patients who eventually developed either monosomy 7 or complex karyotype are depicted as red squares and patients who developed other karyotypic changes are represented as yellow diamonds. (c) Probability of evolution to myelodysplastic syndrome and/or acute leukemia in patients with acquired aplastic anemia and treated with immunosuppression, according to pre-treatment age-adjusted telomere length. Patients were divided into quartiles based on age-adjusted telomere length (first quartile, shorter telomeres; and fourth quartile, longer telomeres). Patients in the shorter quartile (first) had a higher chance to evolve to myelodysplasia and/or leukemia (24.5%) at 5 years in comparison with patients in the second (10.7%), third (4.8%) and fourth (9.7%) quartiles (log-rank, P ¼ 0.06). (d) Probability of evolution to monosomy 7 or complex karyotype in patients with acquired aplastic anemia treated with immunosuppression, according to pre-treatment age-adjusted telomere length. The risk of evolution to these poor prognosis karyotypes was similar (2.5%) in the fourth and third quartiles, somehow higher (8.3%) in the second quartile and significantly higher (18.8%) in patients in the shorter telomere (first) quartile (log-rank, P ¼ 0.018).
were evaluated in cell metaphases by FISH in cultured marrows of aplastic patients (collected 6 months post immunosuppressive therapy) in media enriched with hematopoietic growth factors. Six-month marrow samples were used due to the paucity of cells at diagnosis available for culture in vitro. (Of note, malignant transformation in our series occurred many months to years after that time point (Figure 1c) ). Cells of patients in the lower quartile for average telomere length displayed an increased frequency of telomere signal-free ends in comparison with cells of patients in the upper quartile for average telomere length or to samples from healthy subjects (Figure 2b ).
Short telomeres promote chromosomal aberrations
As shorter average telomere lengths inversely correlated with monosomy 7 at diagnosis and directly corresponded to dysfunctional (signal-free end) telomeres, we investigated whether marrow cells of patients with shorter telomeres had increased proportion of chromosomal aberrations. The same cultured bone marrow samples used to quantify telomere signalfree ends were assayed by SKY in order to detect chromosomal changes. A significant proportion of numeric and structural chromosomal abnormalities were present in metaphase spreads of patients with shorter telomeres compared with patients with longer telomeres or to healthy controls (Table 1) . Patients with Bone marrow samples 6 months after initial therapy were examined for chromosomal telomere-free ends by FISH of healthy subjects (n ¼ 5) and patients with shorter (n ¼ 12) and longer (n ¼ 7) telomeres. The percentage of telomere signal-free chromosomal ends was significantly higher in cells of patients with average length shorter telomeres than in controls or patients with average length longer telomeres (Po0.0001). (c-h) Bone marrow samples of patients with shorter and longer telomeres were analyzed for chromosomal instability by SKY. An increased number of numeric or structural abnormalities were observed in chromosomes of marrow cells of patients with shorter telomeres. Arrows identify the chromosomal abnormalities.
shorter telomeres showed increased frequency of clonal numerical aberrations (w 2 , P ¼ 0.036), structural chromosome defects (w 2 , Po0.001) and chromosome breaks (Table 1 ; Figures 2c-h ).
Telomerase-mutant bone marrow cells and aneuploidy
Although our findings strongly correlated short average telomere lengths and the shortest telomeres with chromosomal instability and the development of clinical disease, they could not directly implicate dysfunctional telomeres in the process. To experimentally approach the difficult issue of causation in human samples, we examined bone marrow cells of individuals who were clinically healthy but who carried a loss-of-function telomerase mutation causing extremely short telomeres. These individuals were identified in family studies of patients with telomerase mutations; they did not have marrow failure or other hematopoietic disease, their blood counts were normal or nearly Ct1 [2] Ct2 [3] del(16)(q?) [1] tas(3;15) (pter;pter) [1] Ct3 [4] Ct3 [7] tas(9;21) (pter;pter) [1] Ct4 [1] Ct4 Pt2 [5] Pt3 [5] der (8) Pt7 [9] Pt8 [7] del (17) normal and their bone marrows were normo-or hypocellular.
As human telomerase-negative cancer cell lines maintain their telomeres using alternative mechanisms, 26 there is no human cell line that adequately recapitulates telomerase deficiency and dysfunctional telomeres analogous to murine telomerase 'knock-out' models. Thus, bone marrow cells of telomerasedeficient subjects with very short telomeres without signs of marrow failure are appropriate surrogates to examine experimentally the effects of telomere shortening on cells without the confounding factors added by disease development.
Telomerase-mutant marrow cells were cultured for 3 days in the presence of high doses of granulocyte-colony stimulating factor, as aneuploid cells are known to proliferate better in this milieu, 27 and FISH was performed before and after cell culture. The number of monosomy-7 and trisomy-8 cells was low in cells of 30 healthy subjects and did not change after culture; however, the proportion of aneuploid cells increased in marrow samples of individuals with telomerase mutations and very short telomeres (P ¼ 0.033; Table 2 ). These results provide direct evidence that eroded telomeres mediate chromosome instability in human hematopoietic cells.
Discussion
In the present study, we demonstrate for the first time in human cells and in a human disease that the shortest telomeres produce chromosomal instability and predispose to malignant transformation. Patients with AA had average leukocyte telomere lengths comparable to age-matched healthy individuals, but bone marrow cells from patients in the shortest quartile for ageadjusted telomere length had a higher frequency of shortest telomeres per cell (telomere signal-free ends), higher proportion of aneuploid cells, higher frequency of structural chromosomal aberrations and ultimately a higher chance of malignant transformation.
In the budding yeast Saccharomyces cerevisiae, telomerase deletion (est1D) causes progressive telomere shortening that associates with increased genomic mutation rates, chromosomal rearrangements and terminal deletions. 28 In murine models for telomerase deficiency, short and dysfunctional telomeres promote chromosomal instability and may lead to epithelial cancers. 16, 17 Also in the telomerase-deficient murine model (Terc À/À ), short telomeres disrupt DNA repair and correlate with increased sensitivity to ionizing radiation. 29 However, the mouse is not an obvious model for human telomere biology and for telomere disease in humans. Laboratory mouse telomeres are 5 to 10 times longer than human telomeres (and they may have lengthened in comparison with mice in the wild, as a result of breeding requirements among mouse fanciers and in scientific laboratories 30 ). Although telomere erosion has been postulated to play a major role in human aging and age-related diseases, laboratory mice have short maximal life spans in comparison with humans and to mice in the wild, and even among laboratory inbred strains telomere length does not correlate with longevity. In humans, patients with telomerase mutations are heterozygous for the mutation and haploinsufficient for telomerase, which may clinically manifest as marrow failure, myelodysplasia, leukemia, pulmonary fibrosis and/or cirrhosis. 3 In contrast, telomerase-haploinsufficient mice (Tert þ /À ) are healthy over 17 generations without manifesting any phenotype similar to a human telomere disease. 31 Considerable manipulation is required to produce a phenotype in the laboratory animal. For example, complete telomerase deficiency achieved by 'knockout' of Tert produces faster and more dramatic telomere shortening, but mice become infertile after six generations before developing overt marrow failure, cancer, cirrhosis, or lung disease. TERT À/À humans have not been reported. Humans deficient in telomerase spontaneously have cirrhosis, but telomerase-deficient mice only develop cirrhosis with chronic chemical injury. 32 Mutations in TERT and TERC associate with pulmonary fibrosis in humans, but paradoxically mice deficient in telomerase are protected from lung fibrosis secondary to bleomycin exposure. 33 Mice have to be engineered with a double 'knockout' combination of Terc and shelterin Pot1b in order to produce some degree of marrow failure and to mimic the human disease. 34 Finally, telomerasedeficient mice only show a higher cancer incidence when coupled with Tp53 deficiency; indeed, when only telomerase is deleted, the cancer incidence is reduced. 35 In humans, telomerase deficiency and/or short telomeres are more consistently associated with significantly increased cancer risk in many organs, including lung cancer, adenocarcinoma, basal cell carcinoma, and urinary bladder, prostate and cervix cancer. 13, 14 In sum, the phenotypic changes caused by telomere attrition in mice do not correlate with human 'telomeropathies' and the mouse cannot be considered an entirely reliable model of telomere biology or telomere diseases in humans. Thus, that short telomeres produce chromosome instability in human cells is important to understand cancer formation in diseases associated with telomere erosion, as in AA and other related diseases.
In the present study, telomere shortening was associated with both numerical and structural chromosome abnormalities. This association is in agreement with previous reports in both murine and human cells. In murine models of telomerase deficiency, telomere shortening induced fusion-bridge breakage that resulted in structural aberrations, 16 and chromosome structural changes occurred more frequently in chromosomes with shorter telomeres. 17 In human epithelial cells, short telomeres related to missegregation of chromosomes and aneuploidy followed on either nondisjunction or anaphase lagging of dicentric chromatids. 36 In addition, telomere dysfunction promoted mitosis bypass and tetraploidy, an intermediate stage of human cancer aneuploidy. 37 Thus, the chromosome abnormalities observed here are probably the result of telomere dysfunction.
Chronic inflammatory disorders are associated with an increased risk of malignant transformation in the chronically injured tissue or organ, but the mechanisms of tumorigenesis are not fully understood. For instance, patients with the chronic inflammation of Barrett esophagus have a higher risk of esophageal adenocarcinoma. 38 Several autoimmune diseases predispose to cancer development in the affected tissue. A prominent example is ulcerative colitis, which incurs an increased risk for colorectal carcinoma. 39 That telomere attrition may mediate cancer development in humans has been suggested in the intestinal mucosa of patients with ulcerative colitis who progress to dysplasia or cancer. 39 However, this study was correlative and retrospective; telomere length was measured in the intestinal mucosa adjacent to the lesion in the same specimen used to diagnose the dysplasia or cancer. In the precancerous condition of Barrett esophagus, the average telomere length of peripheral blood leukocytes was prospectively measured in patients with esophageal inflammation; individuals with shorter telomeres were more likely to later develop esophageal adenocarcinoma. 38 Nevertheless, the link between the telomere lengths of leukocytes and of the esophageal mucosa is unclear and is not necessarily linear. Telomere shortening of blood leukocytes, whereas it may correlate with telomere length in specific tissues, has alternatively been proposed as a biomarker of exposure to reactive oxygen species. 40 Thus, telomere shortening in the esophageal or intestinal mucosa caused by chronic inflammation and oxidative damage may not be reflected in the telomere length of peripheral blood leukocytes. On the basis of these observations, it is not possible to infer from these previous studies whether telomere attrition mediates cancer risk or rather it is a surrogate marker for other molecular events.
In the present study, we provide direct evidence that short telomeres in hematopoietic cells causes chromosome instability and predispose to malignant clonal evolution in the same tissue years before the malignancy appears with clinical manifestations. AA, as a disease of T-cell-mediated destruction of hematopoietic stem cells, shares pathophysiological characteristics with other human immune-mediated, inflammatory, or autoimmune diseases, such as inflammatory bowel disease, uveitis and multiple sclerosis, but the target tissue is more readily accessible and assayed in tissue culture. As a result, we can more directly implicate short telomeres in the mechanism of malignant transformation. In this setting, cells with chromosome instability due to eroded telomeres may be prone to secondary genetic events, such as the deletion of the TP53 gene, and may be selected against normal precursors, with short telomeres more likely to undergo senescence and apoptosis. These combined effects have been previously shown in murine models. 16 Of interest, the TP53 gene was haploinsufficient in cells of two patients with short telomeres analyzed by SKY; in one case there was the appearance of clonal monosomy 17 and in another there was clonal deletion of chromosome 17p13. In fact, telomeres of human chromosome 17p are consistently shorter than the median chromosome telomere length. 41 In conclusion, we show that telomere shortening is a molecular dysfunction that precedes and predisposes to malignant transformation in the human hematopoietic compartment by promoting chromosomal instability. These findings further support the hypothesis that short and dysfunctional telomeres restrict the proliferation of normal hematopoietic stem cells while leading to the selection of genomic unstable stem cells. These findings have immediate clinical implications, as patients with shorter telomeres are at higher risk of malignant transformation, and affected individuals may benefit from therapies that eventually eliminate the shortest (and dysfunctional) telomeres. As telomerase preferentially acts on critically short telomeres, therapeutic telomerase upregulation, for instance by androgens, 3 might reduce the percentage of dysfunctional telomeres in hematopoietic cells and potentially diminish the transformation risk.
